Experience

Davis Polk advised the underwriters in connection with an initial public offering of 8,203,332 shares of common stock of Allakos Inc. at $18.00 per share (which includes the exercise in…

Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” Auris…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ…

Davis Polk advised the representatives of the underwriters in connection with the follow-on offering of 5,175,000 shares of common stock for Natera, Inc. for total gross proceeds of …

Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to purchase up to 700,000 ordinary shares. In addition, Entera Bio Ltd…

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035,000 shares of common stock of Forty Seven, Inc. Forty Seven’s…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…

Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in…

Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock, which included the full exercise of the underwriters’ option to…

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…